3. Materials and Methods
Benzyl 2-diazopropanoate [
20], Methyl 2-diazo-2-phenylacetate [
21] and
tert-Butyl 2-diazopropanoate [
20] were prepared according to literature procedures.
4,16-Dibromo[2.2]paracyclophane (1)
A solution of Br2 (5.50 mL, 17.0 g, 106 mmol, 2.20 equiv.) in CH2Cl2 (50 mL) was prepared. A suspension of iron powder (0.14 g, 2.4 mmol, 0.05 equiv.) in 6.25 mL of the Br2/CH2Cl2 solution was diluted in 50 mL of CH2Cl2 and stirred at room temperature for 1 h. The solution was then brought to reflux for 2 h. CH2Cl2 (50 mL) and [2.2]paracyclophane (10.0 g, 48.0 mmol, 1.00 equiv.) were added to the mixture subsequently. After the remaining bromine solution was added dropwise over a period of 4 h, the mixture was stirred at room temperature for 3 d. Saturated Na2S2O3 solution was added and the reaction mixture was stirred at room temperature until the bromine color disappeared. The organic phase was separated and filtrated, the precipitate was recrystallized from hot toluene to obtain the title product as an off-white solid, 5.40 g, 14.8 mmol, 31%.
1H-NMR (400 MHz, CDCl3) δ/ppm = 7.14 (dd, J = 7.8, 1.8 Hz, 2H, 2 × CArH), 6.51 (d, J = 1.8 Hz, 2H, 2 × CArH), 6.44 (d, J = 7.8 Hz, 2H, 2 × CArH), 3.50 (ddd, J = 12.8, 10.3, 2.0 Hz, 2H, 2 × CHPC), 3.16 (ddd, J = 12.1, 10.2, 4.6 Hz, 2H, 2 × CHPC), 2.95 (ddd, J = 12.1, 11.4, 2.0 Hz, 2H, 2 × CHPC), 2.85 (ddd, J = 13.0, 10.6, 4.6 Hz, 2H, 2 × CHPC). 13C-NMR (101 MHz, CDCl3) δ/ppm = 141.3 (Cq, 2 × CAr), 138.6 (Cq, 2 × CAr), 137.4 (+, CH, 2 × CAr), 134.2 (+, CH, 2 × CAr), 128.4 (+, CH, 2 × CAr), 126.8 (Cq, 2 × CAr-Br), 35.5 (−, 2 × CH2), 32.9 51 (−, 2 × CH2). IR (ATR): /cm−1 = 2932 (vw), 2849 (vw), 1895 (vw), 1583 (vw), 1532 (vw), 1474 (vw), 1449 (vw), 1432 (vw), 1390 (w), 1313 (vw), 1185 (vw), 1104 (vw), 1030 (w), 947 (vw), 899 (w), 839 (w), 855 (w), 830 (w), 706 (w), 669 (w), 647 (w), 522 (vw), 464 (w), 393 (vw). MS (EI, 70 eV), m/z (%): 364/366/368 (3/6/3) [M]+, 184/182 (18/18) [M − C8H7Br]+, 104 (100) [C8H8]+. HRMS (EI, C16H1479Br2) calc. 363.9457, found 363.9455.
(rac)-4,12-Dibromo[2.2]paracyclophane (rac)-2
In a 10 mL microwave vessel was placed 4,16-dibromo[2.2]paracyclophane (500 mg, 1.37 mmol, 1.00 equiv.) and DMF (1.00 mL). The device was programmed to heat the mixture to 180 °C with a holding time set as 6 min. The maximum pressure for the system was set at 17.2 bar and the power was set at 300 W. After cooling to room temperature, the mixture was diluted with DMF (2 mL) and the precipitate was collected by filtration. The reaction was repeated under the same conditions until all the starting material (5.00 g, 13.7 mmol, 1.00 equiv.) reacted. The combined filtrate was poured into water (75 mL) and extracted with EtOAc (3 × 100 mL). The combined organic phase was washed with water and brine, dried over Na2SO4 and concentrated under reduced pressure to give the title product as a pale brown power, 3.50 g, 9.65 mmol, 70%.
Rf = 0.68 (c-Hex/EtOAc = 9:1). 1H-NMR (400 MHz, CDCl3) δ/ppm = 7.22 (d, J = 1.6 Hz, 2H, 2 × CArH), 6.56 (d, J = 7.8 Hz, 2H, 2 × CArH), 6.52 (dd, J = 7.9, 1.7 Hz, 2H, 2 × CArH), 3.47 (ddd, J = 13.3, 9.6, 2.2 Hz, 2H, 2 × CHPC), 3.10 (ddd, J = 13.0, 9.6, 6.8 Hz, 2H, 2 × CHPC), 3.06–2.94 (m, 2H, 2 × CHPC), 2.82 (ddd, J = 13.3, 10.1, 6.9 Hz, 2H, 2 × CHPC). 13C-NMR (101 MHz, CDCl3) δ/ppm = 141.3 (Cq, 2 × CAr), 138.7 (Cq, 2 × CAr), 135.0 (+, CH, 2 × CAr), 132.7 (+, CH, 2 × CAr), 131.7 (+, CH, 2 × CAr), 126.7 (Cq, 2 × CAr-Br), 35.8 (−, 2 × CH2), 32.5 (−, 2 × CH2). IR (ATR): /cm−1 = 2923 (w), 2848 (w), 1583 (w), 1537 (w), 1474 (w), 1449 (w), 1431 (w), 1391 (m), 1272 (w), 1237 (w), 1201 (w), 1185 (w), 1030 (m), 902 (m), 858 (m), 785 (w), 705 (m), 644 (m), 475 (m). MS (70 eV, EI) m/z (%): 368/366/364 (22/43/22) [M]+, 288/286 (13/12) [M + H – Br]+, 184/182 (80/100) [M – C8H6Br]+, 104 (68) [C8H8]+. HRMS (EI, C16H1479Br2) calc. 363.9462, found 363.9461.
(Rp)-4,12-Dibromo[2.2]paracyclophane (Rp-2) / (Sp)-4,12-Dibromo[2.2]paracyclophane (Sp-2)
Separation of (rac)-4,12-dibromo[2.2]paracyclophane (2) was performed by semi-preparative chiral HPLC. For details see Electronic Supporting Information.
(Rp)-4,12-Dicarboxy[2.2]paracyclophane (Rp-3)
To a solution of (Rp)-4,12-dibromo[2.2]paracyclophane (1.50 g, 4.12 mmol, 1.00 equiv.) in abs. THF (50 mL) was added 9.71 mL of t-butyllithium (1.7 M in pentane, 15.4 mmol, 4.00 equiv.) dropwise at −78 °C. After stirring at −78 °C for 3 h, CO2 was bubbled through the solution via a long needle under stirring for 2 h. The reaction mixture was then quenched with water and extracted with 1 M NaOH solution (2 × 100 mL). The water phases were combined, washed with CH2Cl2 (50 mL) and acidified with 6 M HCl until the solution tested acidic by litmus paper. The precipitate was filtrated, washed with water and CH2Cl2. The title product was obtained after drying under high vacuum as white powder, 640 mg, 3.14 mmol, 52%.
[α]
D20 = −134 (c = 0.00203, EtOH).
1H-NMR (400 MHz, DMSO-
d6) δ/ppm = 12.4 (s, 2H, 2 × COOH), 7.04 (d,
J = 2.0 Hz, 2H, 2 × C
ArH), 6.78 (dd,
J = 7.8, 1.9 Hz, 2H, 2 × C
ArH), 6.60 (d,
J = 7.8 Hz, 2H, 2 × C
ArH), 4.04–3.88 (m, 2H, 2 × C
ArH), 3.15 (dd,
J = 12.5, 9.8 Hz, 2H, 2 × C
ArH), 2.98 (ddd,
J = 12.5, 9.6, 7.3 Hz, 2H, C
ArH), 2.81 (ddd,
J = 12.3, 9.8, 7.3 Hz, 2H, 2 × C
ArH).
13C-NMR (101 MHz, DMSO-
d6) δ/ppm = 167.7 (C
q, 2 × COOH), 141.9 (C
q, 2 × C
Ar), 139.7 (C
q, 2 × C
Ar), 136.1 (+, CH, 2 × C
Ar), 135.9 (+, CH, 2 × C
Ar), 133.3 (+, CH, 2 × C
Ar), 130.7 (C
q, 2 × C
Ar-COOH), 35.3 (−, CH
2, 2 × C
PC), 33.7 (−, CH
2, 2 × C
PC). IR (ATR):
/cm
–1 = 2925 (w), 1674 (w), 1592 (w), 1556 (w), 1489 (vw), 1422 (w), 1300 (w), 1273 (w), 1203 (w), 1074 (w), 909 (w), 850 (vw), 797 (vw), 759 (vw), 717 (vw), 664 (w), 631 (w), 555 (vw), 518 (w), 426 (vw). MS (70 eV, EI)
m/
z (%): 296 (27) [M]
+, 278 (100) [MH
2O]
+, 148 (83) [MC
9H
8O
2]
+. HRMS (EI, C
18H
16O
4) calc. 296.1049, found 296.1049. The analytical data match those reported in the literature[
22].
(Rp,S)-4,12-Bis(4′-isopropyloxazolin-2′yl)[2.2]paracyclophane (Rp,S)-4a
Thionyl chloride (1.0 mL) was added to (Rp,S)-4,12-dicarboxy[2.2]paracyclophane (250 mg, 0.840 mmol, 1.00 equiv.) and the resulting mixture was stirred at 100 °C for 90 min. After cooling to room temperature, the excess thionyl chloride was removed under vacuum, the final traces were washed with toluene (2 × 2 mL) and removed under vacuum. The resulting crude acetyl chloride was dissolved in CH2Cl2 (5 mL) and cooled to 0 °C. A solution of S-Valinol (0.350 g, 3.36 mmol, 4.00 equiv.) and Et3N (0.54 mL, 0.42 g, 4.20 mmol, 5.00 equiv.) in CH2Cl2 (1.0 mL) was added, the reaction mixture was allowed to warm to room temperature and stirred for 24 h. 10 mL of CH2Cl2 was then added and the solution was washed with aq. NaHCO3 solution (3.5% w/v, 2 × 10 mL) and brine (20 mL). The organic phase was dried over MgSO4, filtered, concentrated, and dried under vacuum to give the crude amide as light brown solid.
The crude amide was dissolved in CH3CN (5.0 mL), PPh3 (0.66 g, 2.52 mmol, 3.00 equiv.), CCl4 (0.770 mL, 1.23 g, 7.98 mmol, 9.50 equiv.) and Et3N (0.970 mL, 0.760 g, 7.56 mmol, 9.00 equiv.) were added subsequently. After stirring at room temperature overnight, the solvent was removed under reduced pressure, the resulting mixture was dissolved in CH2Cl2 and washed with H2O (2 × 10 mL), the combined organic phase was washed with brine, dried over Na2SO4, filtrated and concentrated under vacuum. The crude was purified via column chromatography (c-Hex/EtOAc = 9:1) to give the title product as a pale yellow solid, 0.150 g, 0.350 mmol, 42%.
Rf = 0.34 (c-Hex/EtOAc = 9:1). 1H-NMR (400 MHz, CDCl3) δ/ppm = 7.09 (d, J = 1.9 Hz, 2H, 2 × CArH), 6.62 (dd, J = 7.9, 1.9 Hz, 2H, 2 × CArH), 6.54 (d, J = 7.8 Hz, 2H, 2 × CArH), 4.37 (ddd, J = 11.2, 9.5, 2.0 Hz, 2H, 2 × CHPC), 4.30 (dd, J = 5.8, 2.2 Hz, 2H, 2 × CH5′), 4.04 (dd, J = 8.6, 6.7 Hz, 2H, 2 × CH4′), 4.05–3.92 (m, 2H, 2 × CH5′), 3.24–3.16 (m, 2H, 2 × CHPC), 3.16–3.07 (m, 2H, 2 × CHPC), 2.82 (ddd, J = 12.6, 10.0, 7.1 Hz, 2H, 2 × CHPC), 1.95 (hept, J = 6.7 Hz, 2H, 2 × CH6′), 1.20 (d, J = 6.7 Hz, 6H, CH7′), 1.06 (d, J = 6.7 Hz, 6H, CH7′). 13C-NMR (101 MHz, CDCl3) δ/ppm = 162.9 (Cq, 2 × C2′), 141.0 (Cq, 2 × CAr), 140.1 (Cq, 2 × CAr), 135.8 (+, CH, 2 × CAr), 134.8 (+, CH, 2 × CAr), 132.3 (+, CH, 2 × CAr), 128.2 (Cq, 2 × CAr), 73.8 (+, CH, 2 × C4′), 69.3 (−, CH2, 2 × C5′), 35.8 (−, CH2, 2 × CPC), 33.6 (+, CH, 2 × C6′), 33.6 (−, CH2, 2 × CPC), 19.7 (+, CH3, 2 × C7′), 19.2 (+, CH3, 2 × C7′). IR (ATR): /cm–1 = 2955 (w), 1637 (m), 1590 (w), 1492 (w), 1468 (w), 1429 (w), 1384 (w), 1346 (w), 1303 (w), 1275 (w), 1258 (w), 1191 (w), 1172 (w), 1137 (w), 1115 (w), 1053 (m), 1026 (w), 984 (m), 933 (w), 907 (m), 889 (w), 822 (w), 749 (w), 694 (w), 674 (w), 643 (w), 514 (w), 482 (vw), 389 (vw). MS (FAB, 3-NBA), m/z (%): 431 (100) [M + H]+, 500/488 (9/9) [C14H17NO2 + H]+. HRMS (FAB, C28H35O2N2, [M + H]+): calc. 431.2699, found 431.2701.
(Rp,S)-4,12-Bis(4′-tertbutyloxazolin-2′yl)[2.2]paracyclophane (Rp,S)-4b
Thionyl chloride (2.0 mL) was added to (Rp)-4,12-dicarboxy[2.2]paracyclophane (0.150 g, 0.510 mmol, 1.00 equiv.), after stirring at room temperature for 10 min, the mixture was heated to 100 °C and stirred at this temperature for 90 min. The excess thionyl chloride was removed by evaporation, the final traces were washed with toluene (2 × 2 mL). After drying under vacuum, the resulting crude acid chloride was dissolved in abs. CH2Cl2 (5 mL) and cooled to 0 °C. A solution of (S)-(+)-tert-leucinol (0.229 g, 2.04 mmol, 4.00 equiv.) and abs. Et3N (0.260 g, 0.360 mL, 2.55 mmol, 5.00 equiv.) in CH2Cl2 (1.0 mL) was added and the reaction mixture allowed to warm to room temperature and stirred for 24 h. Water was then added (10 mL) and extracted with CH2Cl2 (3 × 10 mL), the combined organic phase was washed with sat. NaHCO3 solution and brine (20 mL). The organic phase was dried over MgSO4, filtrated, concentrated, and dried under vacuum. The crude was purified via column chromatography (CH2Cl2/MeOH = 98:2 → 95:5) to give the intermediate amide. To a solution of this amide (152 mg, 0.307 mmol, 1.00 equiv.) and PPh3 (282 mg, 1.08 mmol, 3.50 equiv.) in abs. CH3CN (8.00 mL) was added triethyl amine (0.385 mL, 280 mg, 2.76 mmol, 9.00 equiv.) and CCl4 (0.281 mL, 449 mg, 2.92 mmol, 9.50 equiv.) under argon atmosphere. After stirring at room temperature overnight, the solvent was removed under vacuum, the resulting crude was dissolved in CH2Cl2 and washed with brine, the organic phase was dried over Na2SO4, filtrated and concentrated under vacuum. The resulting mixture was purified via column chromatography (c-Hex/EtOAc = 9:1) to give the title product as colorless solid, 104 mg, 0.227 mmol, 44% over two steps.
Rf = 0.36 (c-Hex/EtOAc = 9:1). 1H-NMR (400 MHz, CDCl3) δ/ppm = 7.12 (d, J = 1.9 Hz, 2H, 2 × CArH), 6.64 (dd, J = 7.8, 1.9 Hz, 2H, 2 × CArH), 6.55 (d, J = 7.8 Hz, 2H, 2 × CArH), 4.33–4.24 (m, 2H, 2 × CH5′), 4.20 (td, J = 8.8, 3.7 Hz, 2H, 2 × CH4′), 4.17–4.08 (m, 4H, 2 × CH5′ + 2 × CHPC), 3.21–3.03 (m, 4H, 4 × CHPC), 2.86–2.68 (m, 2H, 2 × CHPC), 0.99 (s, 18H, CH7′). 13C-NMR (101 MHz, CDCl3) δ/ppm = 162.9 (Cq, 2 × C2′), 141.0 (Cq, 2 × CAr), 140.2 (Cq, 2 × CAr), 135.6 (+, CH, 2 × CAr), 134.7 (+, CH, 2 × CAr), 132.2 (+, CH, 2 × CAr), 128.0 (Cq, 2 × CAr), 74.2 (+, CH, 2 × C4′), 67.7 (−, CH2, 2 × C5′), 36.2 (−, CH2, 2 × CPC), 34.1 (−, CH2, 2 × CPC), 34.0 (Cq, 2 × C6′), 26.1 (+, CH3, 6 × C7′). IR (ATR): /cm−1 = 2951 (w), 2866 (w), 1638 (m), 1590 (w), 1477 (w), 1392 (w), 1350 (w), 1333 (w), 1303 (w), 1257 (w), 1191 (w), 1172 (w), 1113 (w), 1067 (w), 1047 (w), 1024 (w), 979 (m), 930 (w), 906 (w), 819 (w), 791 (w), 719 (w), 679 (w), 632 (w), 544 (vw), 513 (w). MS (FAB, 3-NBA), m/z (%): 459 (82) [M + H]+, 230 (75) [C15H19NO + H]+. HRMS (FAB, C30H39O2N2, [M + H]+): calc. 459.3012, found 459.3011.
(Rp,S)-4,12-Bis(1′-phenyloxazolin-2′yl)[2.2]paracyclophane (Rp,S)-4c
Thionyl chloride (2.0 mL) was added to (Rp)-4,12-dicarboxy[2.2]paracyclophane (0.150 g, 0.510 mmol, 1.00 equiv.), after stirring at room temperature for 10 min, the mixture was heated to 100 °C and stirred under this temperature for 90 min. The excess thionyl chloride was removed by evaporation and the final traces were washed with toluene (2 × 2 mL). After drying under vacuum, the resulting crude acid chloride was dissolved in abs. CH2Cl2 (5 mL) and cooled to 0 °C. A solution of (S)-(+)-phenylglycinol (0.280 g, 2.04 mmol, 4.00 equiv.) and abs. Et3N (0.360 mL, 0.260 g, 2.55 mmol, 5.00 equiv.) in CH2Cl2 (1 mL) was added and the reaction mixture allowed to warm to room temperature and stirred for 24 h. Water (10 mL) was then added, the water phase was extracted with CH2Cl2 (3 × 10 mL) and the combined organic phase was washed with sat. NaHCO3 solution and brine (20 mL). The organic phase was dried over MgSO4, filtered, concentrated, and dried in vacuum. The crude was purified via column chromatography (CH2Cl2/MeOH = 98:2 → 95:5) to give the intermediate amide. To a solution of this amide (200 mg, 0.374 mmol, 1.00 equiv.) and PPh3 (344 mg, 1.31 mmol, 3.50 equiv.) in abs. 10 mL of CH3CN was added Et3N (0.469 mL, 341 mg, 3.37 mmol, 9.00 equiv.) and CCl4 (0.343 mL, 547 mg, 3.55 mmol, 9.50 equiv.) under argon atmosphere. After stirring at room temperature overnight, the solvent was removed under vacuum, the resulting crude was dissolved in CH2Cl2 and washed with brine. The organic phase was dried over Na2SO4, filtrated and concentrated under vacuum, the resulting mixture was purified via column chromatography (c-Hex/EtOAc = 9:1) to give the title product as colorless solid, 177 mg, 0.355 mmol, 95%.
Rf = 0.14 (c-Hex/EtOAc = 9:1). 1H-NMR (500 MHz, CDCl3) δ/ppm = 7.40–7.29 (m, 12H, CH7 + 8′ + 9 + 2 × CArH), 6.70 (dd, J = 7.9, 1.9 Hz, 2H, 2 × CArH), 6.61 (d, J = 7.9 Hz, 2H, 2 × CArH), 5.47 (dd, J = 10.1, 8.2 Hz, 2H, 2 × CH5′), 4.65 (dd, J = 10.1, 8.2 Hz, 2H, 2 × CH5′), 4.44–4.25 (m, 2H, 2 × CHPC), 4.13 (t, J = 8.2 Hz, 2H, 2 × CH4′), 3.22–3.14 (m, 4H, 4 × CHPC), 2.89–2.79 (m, 2H, 2 × CHPC). 13C-NMR (126 MHz, CDCl3) δ/ppm = 164.6 (Cq, 2 × C2′), 143.0 (Cq, 2 × C6′), 141.4 (Cq, 2 × CAr), 140.3 (Cq, 2 × CAr), 135.9 (+, CH, 2 × CAr), 135.1 (+, CH, 2 × CAr), 132.8 (+, CH, 2 × CAr), 128.8 (+, CH, 4 × C8′), 128.5 (Cq, CH, 2 × CAr), 127.5 (+, CH, 2 × C9′), 126.9 (+, CH, 4 × C7′), 73.9 (+, CH, 2 × C4′), 70.7 (−, CH2, 2 × C5′), 36.4 (−, CH2, 2 × CPC), 34.2 (−, CH2, 2 × CPC). IR (ATR): /cm–1 = 2922 (w), 1630 (m), 1589 (w), 1493 (w), 1448 (w), 1349 (w), 1296 (w), 1274 (w), 1245 (w), 1191 (w), 1172 (w), 1136 (vw), 1116 (vw), 1050 (w), 986 (w), 961 (w), 927 (w), 902 (w), 887 (w), 823 (w), 750 (w), 697 (w), 639 (w), 523 (w), 388 (vw). MS (FAB, 3-NBA), m/z (%): 499 (100) [M + H]+, 250 (34) [C17H15NO + H]+. HRMS (FAB, C34H31O2N2, [M + H]+): calc 499.2386, found 499.2386.
Methyl 2-Phenyl-2-(phenylamino)acetate (7a)
General procedure (GP) was followed by adding phenyl-2-diazopropionate (17.6 mg, 1.00 mmol, 1.00 equiv.) and aniline (11.2 mg, 1.20 mmol, 1.20 equiv.) to a suspension of in situ generated Cu-(Rp,S)-4a catalyst. The product 7a was obtained via flash chromatography (c-Hex/EtOAc = 5:1) as colorless solid, 23.6 mg, 0.98 mmol, 98%.
1H-NMR (300 MHz, CDCl3) δ/ppm = 7.42 (d, J = 7.7 Hz, 2H, 2 × CArH), 7.27 (qd, J = 7.5, 6.4, 2.6 Hz, 3H, 3 × CArH), 7.04 (t, J = 7.9 Hz, 2H, 2 × CArH), 6.62 (t, J = 7.3 Hz, 1H, CArH), 6.48 (d, J = 7.7 Hz, 2H, 2 × CArH), 5.01 (d, J = 5.9 Hz, 1H, CHN), 4.88 (s, 1H, NH), 3.65 (s, 3H, OCH3).
The analytical data matches the data reported in the literature [
23].
Methyl 2-phenyl-2-(phenylamino)acetate (7b)
GP was followed by adding phenyl-2-diazopropionate (17.6 mg, 1.00 mmol,1.00 equiv.) and aniline (11.2 mg, 1.20 mmol, 1.20 equiv.) to a suspension of in situ generated Cu-(Rp,S)-4a catalyst. The product 7b was obtained via flash chromatography (c-Hex/EtOAc = 5:1) as colorless solid, 23.6 mg, 0.98 mmol, 98%.
1H-NMR (300 MHz, CDCl3) δ/ppm = 7.42 (d, J = 7.7 Hz, 2H, 2 × CArH), 7.27 (qd, J = 7.5, 6.4, 2.6 Hz, 3H, 3 × CArH), 7.04 (t, J = 7.9 Hz, 2H, 2 × CArH), 6.62 (t, J = 7.3 Hz, 1H, CArH), 6.48 (d, J = 7.7 Hz, 2H, 2 × CArH), 5.01 (d, J = 5.9 Hz, 1H, CHN), 4.88 (s, 1H, NH), 3.65 (s, 3H, OCH3).
The analytical data matches the data reported in the literature[
23].
General Procedure (GP): Copper-Catalyzed N–H Insertion
Cu(MeCN)4PF6 (5 mol%), ligand (6 mol%) and NaBArF (6 mol%) were added into an oven-dried screw vial, evacuated, and backfilled with argon three times. After CH2Cl2 (1 mL) was injected into the vial, the solution was stirred at 40 °C under argon atmosphere overnight. A solution of α-diazopropionates (1.00 equiv.) and aniline (1.20 equiv.) in CH2Cl2 (1 mL) was added dropwise, the mixture was stirred at room temperature for 2 h. The resulting mixture was dried under vacuum and purified via column chromatography (c-Hex/EtOAc = 8:1 or pentane/Et2O = 5:1) to give the products 7a–j.
Benzyl phenylalaninate (7c)
GP was followed by adding benzyl 2-diazopropanoate (19.0 mg, 1.00 mmol, 1.00 equiv.) and aniline (11.2 mg, 1.20 mmol, 1.20 equiv.) to a suspension of in situ generated Cu-(Rp,S)-4a catalyst. The product was obtained as a light-yellow solid (c-Hex/EtOAc = 4:1), 23.9 mg, 0.94 mmol, 94%.
Rf = 0.33 (c-Hex/EtOAc = 5:1). 1H-NMR (300 MHz, CDCl3) δ/ppm = 7.31–7.16 (m, 5H, CH2Ph), 7.15–7.02 (m, 2H, 2 × CArH), 6.73 (tt, J = 7.3, 1.1 Hz, 1H, CArH), 6.63 (dd, J = 8.6, 1.2 Hz, 2H, 2 × CArH), 5.07 (s, 2H, CH2Ph), 4.14 (q, J = 7.0 Hz, 1H, CHN), 3.98 (s, 1H, NH), 1.42 (d, J = 7.0 Hz, 3H, CHCH3).
The analytical data matches the data reported in the literature [
24].
Benzyl (2-methoxyphenyl)alaninate (7d)
GP was followed by adding benzyl 2-diazopropanoate (19.0 mg, 1.00 mmol, 1.00 equiv.) and o-anisidine (14.8 mg, 1.20 mmol, 1.20 equiv.) to a suspension of in situ generated Cu-(Rp,S)-4a catalyst. The product was obtained via column chromatography (c-Hex/EtOAc = 5:1) as a light-yellow solid, 23.3 mg, 0.82 mmol, 82%.
1H-NMR (300 MHz, CDCl3) δ/ppm = 7.40–7.06 (m, 5H, CH2Ph), 6.78–6.66 (m, 2H, 2 × CArH), 6.62 (ddd, J = 8.2, 7.2, 1.6 Hz, 1H, CArH), 6.44 (dd, J = 7.6, 1.6 Hz, 1H, CArH), 5.07 (s, 2H, CH2Ph), 4.64 (s, 1H, NH), 4.12 (q, J = 7.0 Hz, 1H, CHN), 3.76 (s, 3H, OCH3), 1.44 (d, J = 6.9 Hz, 3H, CHCH3). 13C-NMR (75 MHz, CDCl3) δ/ppm = 174.5 (Cq, CO2Bn), 147.2 (Cq, CAr), 136.6 (Cq, CAr), 135.8 (Cq, CAr), 128.6 (+, CH, 2 × CAr), 128.3 (+, CH, CAr), 128.2 (+, CH, 2 × CAr), 121.3 (+, CH, CAr), 117.7 (+, CH, CAr), 110.6 (+, CH, CAr), 109.9 (+, CH, CAr), 66.8 (−, CH2, CH2Ph), 55.5(+, CH3, OCH3), 52.0(+, CH, CHN), 18.9 (+, CH3).
The analytical data matches the data reported in the literature [
24].
Benzyl (3-Methoxyphenyl)alaninate (7e)
GP was followed by adding benzyl 2-diazopropanoate (19.0 mg, 1.00 mmol, 1.00 equiv.) and m-anisidine (14.8 mg, 1.20 mmol, 1.20 equiv.) to a suspension of in situ generated Cu-(Rp,S)-4a catalyst. The product was obtained via column chromatography (c-Hex/EtOAc = 5:1) as light-yellow solid, 15.1 mg, 53%.
1H-NMR (300 MHz, CDCl3) δ/ppm = 7.39–7.27 (m, 5H, CH2Ph), 7.07 (t, J = 8.1 Hz, 1H, CArH), 6.32 (dd, J = 8.2, 2.3 Hz, 1H, CArH), 6.25–6.19 (m, 1H, CArH), 6.16 (t, J = 2.3 Hz, 1H, CArH), 5.16 (s, 2H, CH2Ph), 4.19 (q, J = 6.9 Hz, 1H, CHN), 3.74 (s, 1H, NH), 1.48 (d, J = 6.9 Hz, 3H, CHCH3). 13C-NMR (75 MHz, CDCl3) δ/ppm = 174.3 (Cq, CO2Bn), 160.8 (Cq, CAr), 147.9 (Cq, CAr), 135.5 (Cq, CAr), 130.1 (+, CH, CAr), 128.5 (+, CH, 2 × CAr), 128.3 (+, CH, CAr), 128.1 (+, CH, 2 × CAr), 106.3 (+, CH, CAr), 103.7 (+, CH, CAr), 99.5 (+, CH, CAr), 66.8 (−, CH2, CH2Ph), 55.0 (+, CH3, OCH3), 52.0 (+, CH, CHN), 18.8 (+, CH3).
Benzyl (4-methoxyphenyl)alaninate (7f)
GP was followed by adding benzyl 2-diazopropanoate (19.0 mg, 1.00 mmol, 1.00 equiv.) and p-anisidine (14.8 mg, 1.20 mmol, 1.20 equiv.) to a suspension of in situ generated Cu-(Rp,S)-4a catalyst. The product was obtained via column chromatography (c-Hex/EtOAc = 4:1) as light-yellow solid, 20.0 mg, 70%.
1H-NMR (300 MHz, CDCl3) δ/ppm = 7.38–7.03 (m, 5H, CH2Ph), 6.72–6.61 (m, 2H, 2 × CArH), 6.51 (d, J = 9.0 Hz, 2H, 2 × CArH), 5.06 (s, 2H, CH2Ph), 4.04 (q, J = 6.9 Hz, 1H, CHN), 3.66 (s, 3H, CH3). 13C-NMR (75 MHz, CDCl3) δ/ppm = 175.3 (Cq, CO2Bn), 153.4 (Cq, CAr), 141.2 89 (Cq, CAr), 136.1 (Cq, CAr), 129.1 (+, CH, 2 × CAr), 128.8 (+, CH, CAr), 128.6 (+, CH, 2 × CAr), 115.7 (+, CH, 2 × CAr), 115.4 (+, CH, 2 × CAr), 67.2 (−, CH2, CH2Ph), 56.2 (+, CH3 OCH3,), 53.8 (+, CH, CHN), 19.5 (+, CH3).
The analytical data matches the data reported in the literature[
25].
Benzyl o-tolylalaninate (7g)
GP was followed by adding benzyl 2-diazopropanoate (19.0 mg, 1.00 mmol, 1.00 equiv.) and o-toluidine (12.9 mg, 1.20 mmol, 1.20 equiv.) to a suspension of in situ generated Cu-(Rp,S)-4a catalyst. The product was obtained via column chromatography (c-Hex/EtOAc = 5:1) as colorless solid, 18.3 mg, 0.68 mmol, 68%.
1H-NMR (300 MHz, CDCl3) δ/ppm = 7.44–7.27 (m, 5H, CH2Ph), 7.15–7.05 (m, 2H, Ph), 6.72 (td, J = 7.4, 1.2 Hz, 1H, Ph), 6.55 (dd, J = 8.4, 1.2 Hz, 1H, Ph), 5.19 (s, 2H, CH2Ph), 4.27 (q, J = 6.9 Hz, 1H, CHCH3), 4.08 (s, 1H, NH), 2.21 (s, 3H, CH3), 1.55 (d, J = 6.9 Hz, 3H, CHCH3). 13C-NMR (75 MHz, CDCl3) δ/ppm = 174.7 (Cq, CO2Bn), 144.7 (Cq, CAr), 135.7 (Cq, CAr), 130.5 (Cq, CAr), 128.7 (+, CH, 2 × CAr), 128.4 (+, CH, CAr), 128.2 (+, CH, 2 × CAr), 127.2 (+, CH, CAr), 122.8 (+, CH, CAr), 118.0 (+, CH, CAr), 110.5 (+, CH, CAr), 66.9 (−, CH2, CH2Ph), 52.1 (+, CH, CHN), 19.2 (+, CH3), 17.5 (+, CH3).
Benzyl p-tolylalaninate (7h)
GP was followed by adding benzyl 2-diazopropanoate (19.0 mg, 1.00 mmol, 1.00 equiv.) and p-toluidine (12.9 mg, 1.20 mmol, 1.20 equiv.) to a suspension of in situ generated Cu-(Sp,S)/(Rp,S)-4a catalyst. The product was obtained via column chromatography (c-Hex/EtOAc = 4:1) as light-yellow solid, 18.8 mg, 0.70 mmol, 70%.
Rf = 0.31 (c-Hex/EtOAc = 5:1). 1H-NMR (300 MHz, CDCl3) δ/ppm = 7.34–7.14 (m, 5H, CH2Ph), 6.89 (d, J=8.1 Hz, 2H, 2 × CArH), 6.45 (d, J = 8.4 Hz, 2H, 2 × CArH), 5.06 (s, 2H, CH2Ph), 4.09 (q, J = 7.0 Hz, 1H, CHN), 3.93 (s, 1H, NH), 2.16 (s, 3H, CH3), 1.39 (d, J = 6.9 Hz, 3H, CHCH3). 13C-NMR (75 MHz, CDCl3) δ/ppm = 174.7 (Cq, CO2Bn), 144.4 (Cq, CAr), 135.7 (Cq, CAr), 129.9 (Cq, CAr), 128.6 (+, CH, 2 × CArH), 128.4 (+, CH, CArH), 128.2 (+, CH, 2 × CArH), 127.8 (+, CH, CArH), 113.9 (+, CH, CArH), 66.8 (−, CH2, CH2Ph), 52.6 (+, CH, CHN), 20.5 (+, CH3), 19.0 (+, CH3).
Phenyl phenylalaninate (7i)
GP was followed by adding methyl 2-diazo-2-phenylacetate (17.6 mg, 1.00 mmol, 1.00 equiv.) and aniline (11.2 mg, 1.20 mmol, 1.20 equiv.) to a suspension of in situ generated Cu-(Rp,S)-4a catalyst. The product was obtained via column chromatography (c-Hex/EtOAc = 5:1) as light-yellow liquid, 16.3 mg, 0.68 mmol, 68%.
1H-NMR (300 MHz, CDCl3) δ/ppm = 7.29 (td, J = 7.4, 6.8, 1.3 Hz, 2H, 2 × CArH), 7.20–7.03 (m, 3H, 3 × CArH), 6.98–6.87 (m, 2H, 2 × CArH), 6.72 (tt, J = 7.3, 1.1 Hz, 1H, CArH), 6.64 (dt, J = 7.7, 1.1 Hz, 2H, 2 × CArH), 4.32 (q, J = 7.0 Hz, 1H, CHN), 4.12 (s, 1H, NH), 1.58 (d, J = 6.9 Hz, 3H, CHCH3).
tert-Butyl phenylalaninate (7j)
GP was followed by adding tert-Butyl 2-diazopropanoate (15.6 mg, 1.00 mmol, 1.00 equiv.) and aniline (11.2 mg, 1.20 mmol, 1.20 equiv.) to a suspension of in situ generated Cu-(Rp,S)-4a catalyst. The product was obtained via flash chromatography (c-Hex/EtOAc = 8:1) as a light-yellow liquid, 16.4 mg, 0.74 mmol, 74%.
1H-NMR (300 MHz, CDCl3) δ/ppm = 7.21–7.11 (m, 3H, CArH), 6.73 (t, J = 7.3 Hz, 1H, CArH), 6.61 (d, J = 7.7 Hz, 2H, CArH), 4.02 (q, J = 6.9 Hz, 1H, CHN), 1.44 (s, 9H, C(CH3)3), 1.43 (d, J = 6.9 Hz, 3H). – 13C-NMR (75 MHz, CDCl3) δ/ppm = 174.3 (Cq, CO2tBu), 147.3 (Cq, CAr), 129.8 (+, CH, 2 × CAr), 118.6 (+, CH, CAr), 114.0 (+, CH, 2 × CAr), 82.0 (Cq, C(CH3)3), 53.1 (+, CH, CHNH), 28.5 (+, CH3, 3 × CH3), 19.4 (+, CH3, CHCH3).
The analytical data matches the data reported in the literature [
26].
Methyl 2-phenyl-2-(phenylamino)acetate (14)
GP was followed by adding phenyl-2-diazopropionate (17.6 mg, 1.00 mmol,1.00 equiv.) and aniline (11.2 mg, 1.20 mmol, 1.20 equiv.) to a suspension of in situ generated Cu-(Rp,S)-4a catalyst. The product 7b was obtained via flash chromatography (c-Hex/EtOAc = 5:1) as colorless solid, 23.6 mg, 0.98 mmol, 98%.
1H-NMR (300 MHz, CDCl3) δ/ppm = 7.42 (d, J = 7.7 Hz, 2H, 2 × CArH), 7.27 (qd, J = 7.5, 6.4, 2.6 Hz, 3H, 3 × CArH), 7.04 (t, J = 7.9 Hz, 2H, 2 × CArH), 6.62 (t, J = 7.3 Hz, 1H, CArH), 6.48 (d, J = 7.7 Hz, 2H, 2 × CArH), 5.01 (d, J = 5.9 Hz, 1H, CHN), 4.88 (s, 1H, NH), 3.65 (s, 3H, OCH3).
The analytical data matches the data reported in the literature [
23].